December 14, 2006: Prasad Devarajan, MD and Robert H. Christenson, PhD
Acute kidney injury (AKI) is a common problem, with serious short- and long-term consequences. The diagnosis of AKI is frequently delayed, meaning that potentially effective preventive and therapeutic measures are also frequently delayed due to a lack of early diagnostic markers.
But despite major achievements in treating children and adults with kidney failure, little has changed in the last four decades to diagnose AKI early enough before it progresses into a chronic or deadly condition. Five percent of all patients admitted to the hospital and 30%-50% of those in intensive care units will have kidney failure. In these cases, mortality is in the range of 50% to 80%.
Join us as our experts—Robert Christenson, PhD, from the University of Maryland Medical Center, and Prasad Devarajan of Cincinnati Children's Hospital Medical Center—examine emerging technologies that are yielding novel, early, non-invasive biomarkers for the prediction of AKI.